Navigation Links
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Date:12/5/2012

e project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.  Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and products liability claims.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
3. Amgen Announces 2012 Third Quarter Dividend
4. Amgen to Present at the Leerink Swann Global Healthcare Conference
5. Amgen to Acquire Micromet
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
8. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
9. Amgen Announces 2012 First Quarter Dividend
10. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
11. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... (PRWEB) September 12, 2014 Advancing ... and decontamination of chemical and biological threats is ... by Worcester Polytechnic Institute (WPI) and the Georgian ... the Science for Peace and Security Programme of ... of NATO’s Advanced Research Workshop series, the event ...
(Date:9/12/2014)... (PRWEB) September 12, 2014 Today, “The ... on Indiegogo. , The film, directed by former ... Aldrin, Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and ... and there’s only one university in the world devoted ... change the lives of a billion people: Singularity University. ...
(Date:9/12/2014)... 2014 Sandia Biotech, Inc. announced today ... with STC.UNM (STC) for a technology developed by researchers ... New Mexico, and Queen Mary University of London in ... Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed by ... and Dr. Angray Kang from Queen Mary’s Department of ...
(Date:9/11/2014)... (hiPSCs), researchers have gained new insight into what ... of neuronal signaling associated with this disease. They ... hiPSCs of healthy individuals and of patients with ... cells to release neurotransmitters, such as dopamine, that ... to various disorders. By discovering a simple method ...
Breaking Biology Technology:Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4Stem cells help researchers understand how schizophrenic brains function 2
... 16 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... of the company,s HIV tropism assay were presented ... Drug Resistance Workshop,in Sitges, Spain. Trofile was introduced ... in class CCR5 antagonist, in,August 2007. Recent enhancements ...
... /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ... compound in clinical trial in patients with ... the European Hematology Association,held in Copenhagen, Denmark ... Director R&D, Biology, presented data on,PBI-1402 in ...
... Inc. (Nasdaq: ALXN ) today announced that ... of Alexion,Pharmaceuticals, will present at the William Blair ... a.m., local time (10:10 a.m., eastern) on,Thursday, June ... Sinha,s remarks will be available live. You can,access ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3
(Date:9/12/2014)... attack from a pathogen, they sometimes respond by killing ... committing "cell suicide" to thwart further damage from the ... microscopic, spots or lesions on the plant. , But ... the plant regulates this "spotty" defense mechanism because the ... North Carolina State University have identified a number of ...
(Date:9/12/2014)... of dendritic cells in human skin have assorted functions ... report researchers in the journal EMBO Molecular Medicine ... the composition of dendritic cells in psoriatic skin lesions ... the disease. , "We urgently need new ways ... to patients and reduce the incidence of known side ...
(Date:9/11/2014)... Northumberland and Durham" by Nathaniel John Winch is re-published ... an example of combining modern information technology together with ... and data re-use. This publication will be supporting ongoing ... be seen as a model for other regions in ... the meticulous detail of old books with the interconnectedness ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Dendritic cells affect onset and progress of psoriasis 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
...
... Lyophilized. Lyophilized from 2 mM sodium ... human liver. Cathepsin D is a major ... as a 52 kDa proenzyme. Overexpression of ... associated with higher risk of relapse and ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: